Head-To-Head Analysis: Cardio Diagnostics (NASDAQ:CDIO) vs. Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences (NASDAQ:RNA) and Cardio Diagnostics (NASDAQ:CDIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for Avidity Biosciences and Cardio Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1	12	5	1	2.32
Cardio Diagnostics	1	0	0	0	1.00

Avidity Biosciences presently has a consensus price target of $69.42, suggesting a potential upside of 407.46%. Given Avidity Biosciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Avidity Biosciences is more favorable than Cardio Diagnostics.

Institutional and Insider Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Avidity Biosciences and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%

Volatility & Risk

Avidity Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.

Valuation & Earnings

This table compares Avidity Biosciences and Cardio Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$18.62 million	N/A	-$322.30 million	N/A	N/A
Cardio Diagnostics	$14,825.00	398.93	-$6.50 million	($3.72)	-0.54

Cardio Diagnostics has lower revenue, but higher earnings than Avidity Biosciences.

Summary

Avidity Biosciences beats Cardio Diagnostics on 8 of the 13 factors compared between the two stocks.

About Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.